Peplogue
Back to Sleep & mood

BPC-157

No randomized human results yet; a hamstring trial is recruiting.

A 15-amino-acid fragment of a protein found in stomach juice. In rats it speeds the healing of tendons, muscle and gut. No randomized human trial has published results, and more than 80% of the research comes from one group. Also called Body Protection Compound, PL 14736 and Wolverine stack (BPC-157 + TB-500).

C62H98N16O221,419.6 g/mol15 amino acids

What the evidence shows

Tendon, ligament and muscle injuries
Joints & tendons
Lab only
A 2025 systematic review of sports-injury research found 35 preclinical studies and one human study. A randomized, placebo-controlled trial in 120 people with hamstring strains has been recruiting since February 2026.
Knee pain, injected into the joint
Joints & tendons
Early
One clinic reported on 12 patients with no comparison group. Most said the pain improved.
Ulcers and inflamed bowel
Gut
Lab only
Animal studies, plus two early ulcerative-colitis enema trials that never published full results. A 2015 safety trial of an oral form never reported results.
General tissue healing
Healing & recovery
Lab only
Animal studies only.

Side effects and risks

Serious
Product quality is unverified. The US Department of Defense warns of contamination, and FDA cites the risk of immune reactions to impurities.
Unknown
No clinical safety data, as published reviews state.
Unknown
It promotes new blood-vessel growth in animals. Nobody has tested whether that could help a tumor grow.

Who should avoid it: Anyone with a history of cancer, competitive athletes, and anyone who cannot verify what is in the vial.

Athletes: Prohibited at all times (class S0). Banned as a non-approved substance. Not approved for human use by any health authority. USADA BPC-157 page

How it works

Where it acts
No receptor has been identified. In animals it appears to boost new blood vessels and growth-factor and nitric-oxide signalling.
What it changes
In rats, faster healing of tendons, muscle and the gut lining.
What people notice
No controlled human trial has reported results. People report faster recovery, but placebo and natural healing can explain much of that.

How it has been given in studies

No established human dose. The only published human uses were one-off injections by a doctor into the knee joint or bladder wall, and an intravenous safety test in two volunteers. Self-injections and capsules sold online have no controlled human data.

Getting it in the United States

This describes what people do. It is not advice. The decision is yours.

What users report

Recurring themes in public forum posts, unverified and with no comparison group.

Reported benefits

  • Faster recovery from tendon and joint injuries, the most common claim
  • Calmer stomach

Reported problems

  • Many notice nothing
  • Headache, tiredness, redness at the injection site
  • A minority describe flat mood or anxiety

Injuries often heal on their own, and there is no placebo group to compare with. Products also vary by seller.

More contextCase reports, what public figures say, videos and articles, when options run out and the chemistry

Case reports

From journals, regulators and studies of users. One case proves little.

Harm reportedcase report - 3 people - 2026

FDA told its panel it had three adverse event reports after injection, including nine days of injection-site swelling and an emergency visit for breathlessness. Other drugs were involved and cause could not be judged.

Source: RAPS, 2026-07

Knee injection series reports pain relief

Benefit reportedcase series - 12 people - 2021

A retrospective series of 12 people given BPC-157 injections into the knee reported marked pain relief in 11. A later review notes the series used no validated measure of improvement. The same review says a 42-volunteer phase I safety trial never published results.

Source: Review by Jozwiak et al. on PMC, 2025

What experts and influencers say

Recommend7
Mixed view6
Warn against29

Paraphrased from the linked sources.

Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.

Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025

Eric TopolWebsiteWarns against

Cardiologist, Scripps Research

Devoted a full episode in 2024 to how these peptides are thought to work and how people use them. He presents possible benefits for healing, growth hormone, sleep and libido, and also says most of the data comes from animals, that black-market products may be contaminated, and that anyone with a tumor or cancer concern should avoid peptides that promote growth or new blood vessels.

Source: Huberman Lab episode, 1 Apr 2024

Andrew HubermanInstagramMixed view

Neuroscientist and podcast host

Watch and read

Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.

Article - STAT (co-published with Undark) - 3 Feb 2026 - 22 min

From Croatia to MAHA: How an unapproved drug became the next hot peptide

Sara Talpos, journalist

Traces how BPC-157 moved from bodybuilding circles into the MAHA movement, arguing popularity has outrun evidence, with open questions on safety, conflicts and regulation.

Deepest skeptical reporting on where the hype came from

Article - STAT (co-published with Undark) - 1 Jun 2026 - 20 min

The hidden history of BPC-157, a favorite MAHA peptide

Sara Talpos, journalist

Profiles Predrag Sikiric, the Croatian scientist behind BPC-157 for 50 years, and examines doubts about its evidence and the FDA compounding debate.

The inventor's story, told with scientific skepticism

Podcast - Short Wave (NPR) - Jul 2026

Does the science of peptides live up to the hype?

Sarah Boden, NPR health reporter

Reporter explains why most influencer peptides, including BPC-157, lack human evidence, and what gray-market sourcing and a pending FDA decision mean.

Quick, listenable reality check before the FDA decision

When options run out

Uses people turn to when standard treatment has failed.

Ulcerative colitis

Who
People with inflammatory bowel disease looking beyond standard drugs. This was the use FDA reviewed in 2026.
Evidence
Two enema trials in Croatia in the 2000s were never fully published. FDA staff found a lack of evidence of effectiveness.
Route
FDA panel voted 8-6 in 2026-07 to recommend pharmacy compounding. Rulemaking still required.

Source: RAPS, 2026-07

Interstitial cystitis after pentosan failure

Who
Women with moderate to severe bladder pain syndrome whose standard oral drug did not work.
Evidence
One uncontrolled 12-patient pilot at a private clinic: after one bladder-wall treatment, 10 self-reported full symptom resolution and two partial. No adverse events reported. No controlled trial.

Source: UroToday abstract, 2024

Chronic knee and tendon injuries

Who
Athletes and patients whose joint or tendon pain persists after standard care.
Evidence
A review of 36 studies found 35 preclinical and one 12-patient knee series. A 2015 phase 1 trial has unknown status, and a placebo-controlled hamstring trial began recruiting in February 2026. Neither has reported results.

Source: HSS Journal, 2025

Legal last-resort routes

Expanded access (compassionate use)

For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.

Source: FDA, expanded access for patients

Right to Try

For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.

Source: FDA, Right to Try

Trial finders

Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.

Source: NIH, finding a clinical trial

Personal import for serious conditions

FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.

Source: FDA, personal importation

Patient-specific compounding

When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.

Source: Oregon Board of Pharmacy, Feb 2025

Amino-acid sequence

Water-avoidingPositive chargeNegative chargeStructural

Questions people ask

Does BPC-157 actually work?

In rats it speeds the healing of tendons, muscle and gut, but no randomized human trial has published results. A 2025 systematic review of sports-injury research found 35 preclinical studies and one human study, and more than 80% of the research comes from one group.

Is BPC-157 legal?

In the US, FDA advisers voted 8 to 6 in July 2026 to back compounding, but FDA staff opposed it and FDA had not acted by late September 2026. In Australia it has been Schedule 4 and Appendix D since 1 June 2024, so possession without authority is illegal. Health Canada named it in a 2025 advisory and an April 2026 warning.

What are the side effects of BPC-157?

There are no clinical safety data. Users report headache, tiredness and redness at the injection site, a minority describe flat mood or anxiety, and product quality is unverified.

Can BPC-157 cause cancer?

Nobody knows. It promotes new blood-vessel growth in animals, nobody has tested whether that could help a tumor grow, and people with a history of cancer are advised to avoid it.

What is the Wolverine stack?

A nickname for BPC-157 taken together with TB-500, mostly for injury recovery. No controlled human trial of BPC-157 has reported results.

Your notebook

Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.

Start tracking

Sources

  1. Vasireddi et al. 2025: systematic review of BPC-157
  2. Pharmaceuticals 2025: critique of the BPC-157 evidence
  3. McDermott: July 2026 advisory committee votes
  4. McDermott: state and federal enforcement (24 Sep 2026)
  5. ClinicalTrials.gov: BPC 157 for hamstring strain (NCT07437547)
  6. Operation Supplement Safety (US Defense Department): BPC-157
  7. nference preprint: BPC-157 use in US health records (Sep 2026)
  8. Health Canada: think twice before injecting peptides bought online (9 Apr 2026)
  9. TGA: scheduling decision for BPC-157 (May 2024)

Structure: PubChem